ICT
MCID: CRC014
MIFTS: 40

Carcinoid Tumors, Intestinal (ICT) malady

Categories: Genetic diseases, Endocrine diseases, Rare diseases, Gastrointestinal diseases, Cancer diseases

Aliases & Classifications for Carcinoid Tumors, Intestinal

Aliases & Descriptions for Carcinoid Tumors, Intestinal:

Name: Carcinoid Tumors, Intestinal 54 24 13
Gastrointestinal Carcinoid Tumor 66 52 69
Malignant Carcinoid Syndrome 56 69
Carcinoid Tumor 42 69
Argentaffinoma 66 69
Carcinoid 66 52
Carcinoid Tumor No Icd-O Subtype 69
Carcinoid Tumor of Intestine 69
Intestinal Carcinoid Tumor 66
Carcinoid Syndrome 56
Ict 66

Characteristics:

HPO:

32
carcinoid tumors, intestinal:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 56  
Rare endocrine diseases


External Ids:

OMIM 54 114900
Orphanet 56 ORPHA100093
ICD10 via Orphanet 34 E34.0
MedGen 40 C0349535
MeSH 42 D002276

Summaries for Carcinoid Tumors, Intestinal

UniProtKB/Swiss-Prot : 66 Intestinal carcinoid tumor: A yellow, well-differentiated, circumscribed tumor that arises from enterochromaffin cells in the small intestine or, less frequently, in other parts of the gastrointestinal tract.

MalaCards based summary : Carcinoid Tumors, Intestinal, also known as gastrointestinal carcinoid tumor, is related to zollinger-ellison syndrome and pheochromocytoma, and has symptoms including intestinal carcinoid An important gene associated with Carcinoid Tumors, Intestinal is SDHD (Succinate Dehydrogenase Complex Subunit D), and among its related pathways/superpathways is Neuroscience. The drugs Oxaliplatin and Somatostatin have been mentioned in the context of this disorder. Affiliated tissues include small intestine, and related phenotypes are cardiovascular system and homeostasis/metabolism

Description from OMIM: 114900

Related Diseases for Carcinoid Tumors, Intestinal

Diseases related to Carcinoid Tumors, Intestinal via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 193)
id Related Disease Score Top Affiliating Genes
1 zollinger-ellison syndrome 29.7 CHGA SDHD SYP
2 pheochromocytoma 28.4 CHGA CHGB MEN1 POMC SDHD SST
3 carcinoid syndrome 12.4
4 duodenal carcinoid syndrome 11.8
5 pellagra 11.1
6 serotonin syndrome 10.7
7 gastrointestinal system benign neoplasm 10.3 CHGA NKX2-1
8 secondary syphilis 10.3 CHGA SST
9 brain edema 10.3 CHGA SST
10 peroneal nerve paralysis 10.2 CHGA SYP
11 oculocutaneous albinism 10.2 CHGA SST
12 thymus small cell carcinoma 10.2 CHGA SYP
13 brain stem ependymoma 10.2 CHGA SYP
14 non specific chronic endometritis 10.2 CHGA SYP
15 extrahepatic biliary papillomatosis 10.2 CHGA SYP
16 prolactin producing pituitary tumor 10.2 CHGA SYP
17 epithelioid malignant peripheral nerve sheath tumor 10.2 CHGA SYP
18 cartilage cancer 10.2 CHGA SYP
19 jejunal neuroendocrine tumor 10.2 CHGA SYP
20 volkmann contracture 10.2 CHGA SST
21 renal pelvis adenocarcinoma 10.2 CHGA SYP
22 barre-lieou syndrome 10.2 CHGA SYP
23 microinvasive cervical squamous cell carcinoma 10.2 CHGA SYP
24 spinal stenosis 10.2 CHGA SST
25 kidney disease 10.2 NKX2-1 SYP
26 perineural angioma 10.2 CHGA SYP
27 bone deterioration disease 10.2 NKX2-1 SYP
28 gastric duplication cysts 10.2 CHGA SYP
29 diffuse cutaneous mastocytosis 10.2 CHGA SYP
30 main bronchus cancer 10.2 CHGA SYP
31 gliofibroma 10.2 CHGA SYP
32 superior vena cava syndrome 10.2 CHGA SYP
33 postgastrectomy syndrome 10.2 SST SYP
34 fragile x-associated tremor/ataxia syndrome 10.2 CHGA SYP
35 hepatorenal syndrome 10.2 CHGA SYP
36 adult ependymoblastoma 10.2 CHGA MEN1
37 glomangioma 10.2 SDHD SYP
38 burning mouth syndrome type 3 10.2 POMC SST
39 renal hypoplasia, bilateral 10.2 POMC SST
40 acalculous cholecystitis 10.2 CHGA SYP
41 piussan lenaerts mathieu syndrome 10.2 CHGA SYP
42 water-clear cell adenoma 10.2 POMC SST
43 hepatitis 10.2
44 brain stem astrocytic neoplasm 10.2 CHGA SYP
45 vaginal adenoma 10.2 POMC SST
46 parietal lobe neoplasm 10.2 CHGA POMC
47 anal squamous cell carcinoma 10.2 CHGA SYP
48 duodenal obstruction 10.2 NKX2-1 SYP
49 uterine corpus myxoid leiomyosarcoma 10.2 CHGA SYP
50 african histoplasmosis 10.2 POMC SST

Graphical network of the top 20 diseases related to Carcinoid Tumors, Intestinal:



Diseases related to Carcinoid Tumors, Intestinal

Symptoms & Phenotypes for Carcinoid Tumors, Intestinal

Symptoms by clinical synopsis from OMIM:

114900

Clinical features from OMIM:

114900

Human phenotypes related to Carcinoid Tumors, Intestinal:

32
id Description HPO Frequency HPO Source Accession
1 intestinal carcinoid 32 HP:0006723

MGI Mouse Phenotypes related to Carcinoid Tumors, Intestinal:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 CHGA MEN1 NKX2-1 NOTCH1 POMC SDHD
2 homeostasis/metabolism MP:0005376 9.81 CHGA CHGB MEN1 NKX2-1 NOTCH1 POMC
3 endocrine/exocrine gland MP:0005379 9.8 CHGA CHGB MEN1 NKX2-1 NOTCH1 POMC
4 digestive/alimentary MP:0005381 9.72 MEN1 NKX2-1 NOTCH1 SST SSTR2
5 neoplasm MP:0002006 9.35 POMC SDHD MEN1 NKX2-1 NOTCH1
6 nervous system MP:0003631 9.28 SST SSTR2 SYP CHGB MEN1 NKX2-1

Drugs & Therapeutics for Carcinoid Tumors, Intestinal

Drugs for Carcinoid Tumors, Intestinal (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 229)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
2
Somatostatin Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 38916-34-6, 51110-01-1 53481605
3 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
4 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
5 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Hypoglycemic Agents Phase 4,Phase 2,Early Phase 1
9 insulin Phase 4,Phase 2
10 Insulin, Globin Zinc Phase 4,Phase 2
11 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
13
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
14
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
15
lanreotide Approved Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
16
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
17
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
18
Octreotide Approved, Investigational Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
19
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
21
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
22
Ondansetron Approved Phase 3 99614-02-5 4595
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
24
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 54575, 6560146 143
25 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
26 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
27 Antimetabolites Phase 2, Phase 3,Phase 1
28 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
29 Immunosuppressive Agents Phase 2, Phase 3, Phase 1
30 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
31 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
32 Anti-Infective Agents Phase 3,Phase 2,Phase 1
33 Gastrointestinal Agents Phase 3,Phase 1,Phase 2
34 HIV Protease Inhibitors Phase 3,Phase 2
35
protease inhibitors Phase 3,Phase 2
36 Antiviral Agents Phase 3,Phase 2,Phase 1
37 Interferon-alpha Phase 3,Phase 2
38 interferons Phase 3,Phase 2,Phase 1
39 Angiopeptin Phase 3,Phase 2,Phase 1,Early Phase 1
40 Pharmaceutical Solutions Phase 3,Phase 2
41 Antifungal Agents Phase 3,Phase 2,Phase 1
42 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
43 Adjuvants, Anesthesia Phase 3
44 Analgesics Phase 3,Phase 1
45 Analgesics, Opioid Phase 3
46 Anesthetics Phase 3,Phase 2
47 Anesthetics, General Phase 3
48 Anesthetics, Intravenous Phase 3
49 Central Nervous System Depressants Phase 3
50 Narcotics Phase 3

Interventional clinical trials:

(show top 50) (show all 200)
id Name Status NCT ID Phase
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
3 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4
4 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
5 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
6 An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Completed NCT00774930 Phase 3
7 Telotristat Etiprate for Carcinoid Syndrome Therapy Completed NCT02063659 Phase 3
8 TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Completed NCT01677910 Phase 3
9 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Completed NCT00412061 Phase 3
10 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
11 Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease Completed NCT00690430 Phase 3
12 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3
13 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
14 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs Recruiting NCT01842165 Phase 3
15 Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Active, not recruiting NCT02026063 Phase 3
16 A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Active, not recruiting NCT01578239 Phase 3
17 [68 Ga]-DOTANOC PET/CT in GEP-NETs Not yet recruiting NCT02608203 Phase 2, Phase 3
18 Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3
19 Randomized Phase III of PRRT Versus Interferon Withdrawn NCT01860742 Phase 3
20 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2
21 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
22 Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors Unknown status NCT01177007 Phase 2
23 The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer Unknown status NCT01739634 Phase 1, Phase 2
24 IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma Unknown status NCT00294476 Phase 2
25 Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer Unknown status NCT00553683 Phase 1, Phase 2
26 Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2
27 Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Completed NCT00853047 Phase 2
28 Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2
29 Phase II Study of Subcutaneous Injection Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Completed NCT02299089 Phase 2
30 Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Completed NCT00002470 Phase 2
31 Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
32 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2
33 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2
34 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2
35 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2
36 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2
37 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2
38 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2
39 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2
40 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2
41 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
42 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
43 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Completed NCT00903396 Phase 2
44 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2
45 The Safety and Efficacy of CPTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors Completed NCT00627198 Phase 2
46 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET Completed NCT02162446 Phase 1, Phase 2
47 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2
48 Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases Completed NCT01290536 Phase 2
49 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2
50 Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer Completed NCT00002475 Phase 2

Search NIH Clinical Center for Carcinoid Tumors, Intestinal

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: carcinoid tumor

Genetic Tests for Carcinoid Tumors, Intestinal

Genetic tests related to Carcinoid Tumors, Intestinal:

id Genetic test Affiliating Genes
1 Carcinoid Tumors, Intestinal 24 SDHD

Anatomical Context for Carcinoid Tumors, Intestinal

MalaCards organs/tissues related to Carcinoid Tumors, Intestinal:

39
Small Intestine

Publications for Carcinoid Tumors, Intestinal

Variations for Carcinoid Tumors, Intestinal

Expression for Carcinoid Tumors, Intestinal

Search GEO for disease gene expression data for Carcinoid Tumors, Intestinal.

Pathways for Carcinoid Tumors, Intestinal

Pathways related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.43 NKX2-1 NOTCH1 POMC SYP

GO Terms for Carcinoid Tumors, Intestinal

Cellular components related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 8.8 CHGA CHGB POMC

Biological processes related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 brain development GO:0007420 9.58 MEN1 NKX2-1 NOTCH1
2 negative regulation of cell proliferation GO:0008285 9.46 MEN1 NOTCH1 SST SSTR2
3 negative regulation of osteoblast differentiation GO:0045668 9.43 MEN1 NOTCH1
4 oligodendrocyte differentiation GO:0048709 9.37 NKX2-1 NOTCH1
5 neuron fate commitment GO:0048663 9.32 NKX2-1 NOTCH1
6 endoderm development GO:0007492 9.26 NKX2-1 NOTCH1
7 negative regulation of cell-substrate adhesion GO:0010812 8.96 MEN1 NOTCH1
8 forebrain development GO:0030900 8.8 NKX2-1 NOTCH1 SSTR2

Molecular functions related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 CHGB POMC SST

Sources for Carcinoid Tumors, Intestinal

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....